Lindbrook Capital, LLC Esperion Therapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.09 Billion
- Q4 2024
A detailed history of Lindbrook Capital, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 255 shares of ESPR stock, worth $474. This represents 0.0% of its overall portfolio holdings.
Number of Shares
255
Previous 255
-0.0%
Holding current value
$474
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ESPR
# of Institutions
217Shares Held
127MCall Options Held
1.61MPut Options Held
1.1M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$45.5 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.8 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.5 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.7 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $124M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...